Acimmune SA (IMR)
XFRA 
Summary
IMR Chart
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease (PD) Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025 Presentations at International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) highlight leadership in active immunotherapy and promising data on early-stage assets Cash resources of CHF 145.7 million as of March 31, 2025 provide funding into Q1 2027 before any potential milestones Lausanne, Switzerland, April 30, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended March 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune's portfolio of active immunotherapies for precision prevention of neurodegeneration continues to advance in clinical development.
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) taking place in Vienna, Austria, on April 1 – 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership.
Acimmune SA Dividends
Acimmune SA Earnings
| 4 Aug 2025 (62 Days) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Mar 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 1 Nov 2024 Date | | - Cons. EPS | - EPS |
| 4 Aug 2025 (62 Days) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Mar 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 1 Nov 2024 Date | | - Cons. EPS | - EPS |
Acimmune SA (IMR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Acimmune SA ever had a stock split?
Acimmune SA Profile
| Biotechnology Industry | Healthcare Sector | Dr. Andrea Pfeifer Ph.D. CEO | XFRA Exchange | CH0329023102 ISIN |
| CH Country | 133 Employees | - Last Dividend | - Last Split | 23 Sep 2016 IPO Date |
Overview
AC Immune SA is a clinical stage biopharmaceutical company engaged in the discovery, design, and development of therapeutic and diagnostic products aimed at combating neurodegenerative diseases caused by protein misfolding. Utilizing its proprietary SupraAntigen and Morphomer platforms, the company focuses on creating vaccines, antibodies, and small molecules that specifically target misfolded proteins associated with various neurodegenerative conditions. Through collaborations with leading pharmaceutical entities and its innovative research in the field, AC Immune SA seeks to address the unmet needs in the treatment and diagnosis of these complex diseases. Founded in 2003, the company is based in Lausanne, Switzerland, showcasing its global reach and commitment to improving patients' lives affected by neurodegenerative diseases.
Products and Services
-
Crenezumab
This humanized, conformation-specific monoclonal antibody is in Phase II clinical trial stage, targeting the treatment of Alzheimer's disease (AD). Crenezumab showcases AC Immune’s focus on addressing the critical need for effective treatments against AD.
-
ACI-24
An anti-Abeta vaccine candidate currently in Phase II clinical study for Alzheimer's disease, and has completed Phase Ib for Down syndrome. ACI-24 demonstrates the company’s innovative approach to vaccine development for neurodegenerative diseases.
-
ACI-35
This anti-Tau vaccine candidate is undergoing Phase Ib/2a clinical study, emphasizing the company's dedication to targeting Tau pathology in neurodegenerative disorders, particularly Alzheimer's disease.
-
Tau-positron emission tomography (PET) imaging tracer
Currently in Phase II clinical study, this diagnostic tool represents AC Immune’s commitment to advancing Alzheimer's disease diagnostics by improving the detection of Tau pathology in patients.
-
Small Molecule Tau Aggregation Inhibitors
These compounds are being researched and developed for Alzheimer's disease and NeuroOrphan indications, showcasing AC Immune’s efforts in creating targeted treatments for a range of neurodegenerative conditions through small molecule therapeutics.
-
Discovery and Preclinical Stage Molecules
Focusing on a range of neurodegenerative diseases, these molecules are under exploration for the development of diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. This effort reflects the company's comprehensive approach to tackle the various aspects of neurodegenerative diseases beyond Alzheimer's.
Contact Information
